Dr. Daniel P. Petrylak sits down with CURE during Bladder Cancer Awareness Month to discuss key topics for patients with the ...

AstraZeneca has licensed in an antisense drug from Ionis Pharmaceuticals to treat kidney disease in a deal worth up to $330 million. Antisense drugs contain non-coding strands of mRNA that block ...

Swedish drugmaker Orexo, best known for its opioid addiction therapies, has licensed rights to a digital therapy that marks its first foray into the alcohol dependence category. The deal gives ...

AstraZeneca has announced positive high-level results from its Phase III POTOMAC trial assessing the efficacy of IMFINZI® ...

The analysis by Ontada tracked testing rates withing the US Oncology Network for PD-L1, FGFR2/3, and HER2 biomarkers over 10 years.